Analysis of the overall survival and main surrogates used for FDA approvals in solid and haematological malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz244.048
Abstract: Abstract Background U.S. Food and Drug Administration (FDA) approves drugs based on overall survival (OS) in oncology trials in order to speed up access of novel drugs to the market. Methods We examined all adult… read more here.
Keywords: fda approvals; overall survival; oncology; subsequent lines ... See more keywords